The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib

BACKGROUND & AIMS: It is unknown whether the addition of locoregional therapies (LRTx) to sorafenib improves prognosis over sorafenib alone in patients with advanced hepatocellular carcinoma (HCC). The aim of this study was to assess the effect of LRTx in this population. METHODS: A retrospectiv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:HPB (Oxford)
Hlavní autoři: Sarpel, Umut, Spivack, John H., Berger, Yaniv, Heskel, Marina, Aycart, Samantha N., Sweeney, Robert, Edwards, Martin P., Labow, Daniel M., Kim, Edward
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4857060/
https://ncbi.nlm.nih.gov/pubmed/27154804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hpb.2016.02.007
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky